Seqens Group, an integrated developer and manufacturer of active pharmaceutical ingredients (APIs) and intermediates, has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 sq.-ft. R&D center in Devens, MA. Serving as one of the company’s global centers of excellence, the new facility will provide advanced capabilities for the discovery and development of new drugs and therapeutics.    The company invested $5 million in the new facility that features advanced technologies, equ...